26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.370 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB86

Author(s):

Kim A. Papp ◽

Mark G. Lebwohl ◽

Lluís Puig ◽

Jiewei Zeng ◽

Simone Rubant ◽

...

Keyword(s):

Interim Analysis ◽

Efficacy And Safety ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Faculty Opinions recommendation of Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727479881.793555215 ◽

2019 ◽

Author(s):

Roser Torra

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Efficacy And Safety ◽

Polycystic Kidney ◽

Delayed Treatment ◽

Open Label Extension ◽

Autosomal Dominant Polycystic Kidney ◽

Extension Trial

Download Full-text

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study

PLoS Medicine ◽

10.1371/journal.pmed.1003222 ◽

2020 ◽

Vol 17 (9) ◽

pp. e1003222 ◽

Author(s):

Edward C. Smith ◽

Laurie S. Conklin ◽

Eric P. Hoffman ◽

Paula R. Clemens ◽

Jean K. Mah ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Interim Analysis ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label Extension

Download Full-text

Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the envision open label extension

Journal of Hepatology ◽

10.1016/s0168-8278(20)30664-4 ◽

2020 ◽

Vol 73 ◽

pp. S62-S63

Author(s):

Eliane Sardh ◽

Manisha Balwani ◽

David Rees ◽

Penelope Stein ◽

Ulrich Stözel ◽

...

Keyword(s):

Interim Analysis ◽

Efficacy And Safety ◽

Open Label Extension

Download Full-text

Long-term Efficacy and Safety of Fitusiran in Participants with Hemophilia A and B: An Interim Analysis of the Phase 1/2 Open-Label Extension Study

10.1055/s-0041-1728092 ◽

2021 ◽

Author(s):

C Négrier ◽

MV Ragni ◽

KJ Pasi ◽

SW Pipe ◽

I Hegemann ◽

...

Keyword(s):

Interim Analysis ◽

Hemophilia A ◽

Phase 1 ◽

Extension Study ◽

Efficacy And Safety ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

1.5 Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar Depression: Interim Analysis of a Two-Year Open-Label Extension Study

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2018.09.022 ◽

2018 ◽

Vol 57 (10) ◽

pp. S137

Author(s):

Robert S. Goldman ◽

Melissa P. DelBello ◽

Michael Tocco ◽

Andrei A. Pikalov ◽

Ling Deng ◽

...

Keyword(s):

Children And Adolescents ◽

Interim Analysis ◽

Bipolar Depression ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label Extension

Download Full-text

S1169 Twelve-Month Interim Analysis of Efficacy and Safety of Givosiran, an Investigational RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open Label Extension

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000706724.29564.0b ◽

2020 ◽

Vol 115 (1) ◽

pp. S584-S585

Author(s):

Eliane Sardh ◽

Manisha Balwani ◽

David C. Rees ◽

Penelope Stein ◽

Ulrich Stölzel ◽

...

Keyword(s):

Interim Analysis ◽

Efficacy And Safety ◽

Open Label Extension

Download Full-text

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(16)30430-1 ◽

2017 ◽

Vol 5 (1) ◽

pp. 51-60 ◽

Author(s):

Noel G McElvaney ◽

Jonathan Burdon ◽

Mark Holmes ◽

Allan Glanville ◽

Peter A B Wark ◽

...

Keyword(s):

Proteinase Inhibitor ◽

Efficacy And Safety ◽

Term Efficacy ◽

Antitrypsin Deficiency ◽

Open Label Extension ◽

Extension Trial ◽

Inhibitor Treatment

Download Full-text

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfx079 ◽

2017 ◽

Vol 32 (7) ◽

pp. 1262-1262 ◽

Author(s):

Vicente E. Torres ◽

Arlene B. Chapman ◽

Olivier Devuyst ◽

Ron T. Gansevoort ◽

Ronald D. Perrone ◽

...

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Efficacy And Safety ◽

Polycystic Kidney ◽

Delayed Treatment ◽

Open Label Extension ◽

Autosomal Dominant Polycystic Kidney ◽

Extension Trial

Download Full-text

EIGHTEEN-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2021.10.010 ◽

2021 ◽

Vol 43 ◽

pp. S5-S6

Author(s):

D Kuter ◽

S Keel ◽

C Parker ◽

DC Rees ◽

U Stölzel ◽

...

Keyword(s):

Interim Analysis ◽

Efficacy And Safety ◽

Open Label Extension

Download Full-text